New combo eye drop could simplify Post-Cataract care

NCT ID NCT07305987

Recruiting now Disease control Sponsor: Laboratorios Sophia S.A de C.V. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new eye drop called PRO-232, which combines an antibiotic (moxifloxacin) and a steroid (dexamethasone) in one bottle. It aims to see if this single drop works as well as using two separate drops to prevent infection and control inflammation after cataract surgery. The study will enroll 134 adults and measure how well the eye heals and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRO-232 (moxifloxacin and dexamethasone) ophthalmic solution
What this could lead to: If it works, this could offer a simpler, single-bottle eye drop to prevent infection and control inflammation after cataract surgery, replacing the need for two separate drops.
What could go wrong: This is a Phase 3 trial, but it's relatively small (134 people) and compares to existing treatments, so any advantage may be modest. Side effects from the antibiotics or steroids are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT EXTRACTION

Contacts and locations

Locations

RGH Integra
RECRUITING

Puebla City, Puebla, 72180, Mexico
Retina Center
RECRUITING

Tijuana, Estado de Baja California, 22010, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.